Health & Food · October 23, 2026
The woman was Kenya’s third confirmed case and a close relative of its first. Officials said seven patients remained in care and reported no evidence of community spread.
Read the full report
U.S. · October 22, 2026
Means was a visible inside advocate for the administration’s health and food agenda. His departure comes amid broader MAHA discontent, but he did not say why he was leaving.
Reporting draws on 5 named sources.
Business & Markets · October 19, 2026
The proposed cash acquisition values Silence Therapeutics’ equity at about $1.3 billion. Its lead RNAi medicine remains in clinical development, and closing is not assured.
Reporting draws on 5 named sources.
Business & Markets · October 19, 2026
Hansoh will lead two preclinical programs through Phase Ia, while Roche gets development rights outside Greater China. The headline figure depends on future milestones and is not guaranteed revenue.
Reporting draws on 3 named sources.
Health & Food · October 12, 2026
The official tally is nearing last year’s full-year admission count, but it tracks people treated in hospitals—not every dengue infection in the country.
Reporting draws on 5 named sources.
Health & Food · October 12, 2026
A Holy See update says postoperative tests are normal and Leo has begun walking and eating regular meals. It gives no cancer staging or treatment details; the Vatican still had a November trip scheduled, while its feasibility remains uncertain.
Reporting draws on 9 named sources.
Health & Food · October 8, 2026
The planned study compares about 100,000 users with a similar-sized group and will use FDA Sentinel data. The filing gives a timeline, not results or a decision to change dispensing rules.
Reporting draws on 2 named sources.
Health & Food · October 7, 2026
WHO says it is seeking details about the first worker's severe pneumonia and media reports of a second employee with an illness of undetermined cause. Russia has reported no plague cases in Irkutsk, and WHO's initial risk assessment was very low for Europe.
Reporting draws on 4 named sources.
Health & Food · October 6, 2026
The patient arrived from Uganda on Oct. 3 after falling ill in Congo. Kenya and WHO say response teams are tracing contacts; WHO has not recommended travel or trade restrictions based on information available Tuesday.
Reporting draws on 4 named sources.
Business & Markets · October 6, 2026
The medical-device maker says it will add about five billion domestic medical consumables a year and make all needles for U.S. use with American steel. Those production targets are company commitments, while the tariff deal's financial value is still unknown.
Reporting draws on 3 named sources.
Business & Markets · October 4, 2026
Alentis may also receive up to $1.2 billion in commercial milestones, while development funding sits outside that ceiling. The drug remains experimental, with its lead program still in Phase 2.
Reporting draws on 4 named sources.
Business & Markets · October 2, 2026
The agreement gives Novartis worldwide rights to an mRNA-encoded T-cell engager and options on other platform assets. A three-patient report offers early evidence, not proof that the approach works broadly in autoimmune disease.
Reporting draws on 6 named sources.
Business & Markets · September 12, 2026
The discussions could still end without a deal as J&J weighs a sale against its previously announced separation plan.
Reporting draws on 5 named sources.
Health & Food · September 4, 2026
The report counted 65 health zones historically affected across seven provinces, with 57 still reporting cases as of Oct. 11.
Reporting draws on 5 named sources.